Arrowhead Pharmaceuticals Inc at Jefferies Virtual London Healthcare Conference Transcript
Hi. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. It's with great pleasure that I'd like to welcome Chris Anzalone, CEO of Arrowhead Pharmaceuticals. We're going to do a fireside chat today. So Chris, thanks for joining us. Maybe to start off, if you want to give a brief intro to Arrowhead for those who may not be familiar with the story.
Sure. So Maury, thank you very much for having us. Of course, thank you, Jefferies, for having us. It's a great pleasure to be here by virtual fire. So look -- so Arrowhead is an RNAi company. Our idea here is to silence target genes that cause disease. I think that we are unique in that we are bringing that technology around the body. I think we've got maybe the largest RNAi clinical pipeline in the business; if not now, shortly. We have said that we think we can get into new cell type every 18 to 24 months, and we said that we can
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
